10 nov: Aktietilbagekøbsprogram
10 nov: Indre værdi af SmallCap Danmark A/S er opgjort til 82,7 kr. pr. ..
10-11-2017 07:30:00

Nine-month interim report (Q3) 2017

Relateret indhold
08 maj - 
Aktier/middag: WDH og Lundbeck tager hver sin ende af f..
08 maj - 
Aktier/åbning: Lundbeck og Genmab belønnet for nyt - WD..
08 maj - 
Aktier/tendens: Nyt fra Lundbeck, Genmab og WDH kan tag..
Relateret debat
16 maj - 
Argh......... 2000 på kort sigt er nok ikke s&ari..
16 maj - 
Alk forsøger sig igen med 1000 Sandheden er vel,..
08 maj - 
1000 +          

København, 2017-11-10 07:30 CET (GLOBE NEWSWIRE) --

 

Bemærk venligst, at kvartalsrapporten kun foreligger på engelsk.  

Performance for the period (unaudited)

(Comparative figures for 2016 are shown in brackets. Revenue growth is measured in local currencies. 2016 comparative figures are affected by last year's market disruptions which boosted ALK's sales and earnings in Europe significantly. To provide a meaningful benchmark, comparisons to figures from 2015 have also been included in the report wherever relevant.)

During Q3 2017, ALK continued its investment programme to scale-up and build a pharma company in North America, defend its European leadership position and upgrade its product supply. ALK will continue to invest to deliver its long-term growth plans.    

Q3 2017 highlights:

  • Sales growth in Europe, North America and International markets showed good progress in line with expectations.

  • Total revenue increased 7% to DKK 667 million (630), with European revenue 23% higher organically than 'pre-market disruption' levels in Q3 2015.

  • Constraints in SCIT production capacity are estimated to have negatively impacted Q3 sales by DKK 50-60 million.

  • Operating profit (EBITDA) was DKK 36 million (110) following planned cost increases to support long-term growth, including the launch of the HDM SLIT-tablet in North America and to secure robustness in ALK's product supply operations.

  • 9M total revenue amounted to DKK 2,147 million (2,251) and 9M operating profit (EBITDA) was DKK 192 million (546).

Business priorities

  • Investments in the North American scale-up to support the launch of SLIT-tablets are ongoing. In August, the marketing authorisations were transferred to ALK from the FDA. In November, ALK has launched the HDM SLIT-tablet as ACARIZAX® in Canada and has started pre-launch and marketing activities ahead of the launch in the USA, where the brand name will be ODACTRA™. Market access in the USA is progressing well.

  • Investments to defend and retain market leadership in Europe continue and showed good results in Q3.

  • ACARIZAX® sales in Europe roughly doubled in Q3, while development, registration and market access activities are progressing.

  • Investments in securing a robust product supply continue. Robust inventory levels are expected to be gradually rebuilt during 2018.

  • In December 2017, ALK will be presenting an updated strategy that is designed to stimulate a new era of growth by continuing ALK's investments in its core AIT franchise while also leveraging its position and expertise to engage with more patients and to capture a larger share of the total allergy market.

2017 financial guidance

ALK's financial guidance for full-year revenue has been narrowed while guidances for operating profit (EBITDA) and free cash flow remain unchanged:

  • Full-year revenue is now projected at approximately DKK 2.9 billion (previously DKK 2.8-3.0 billion) as European markets establish a 'new normal' following last year's disruptions. 

  • Operating profit (EBITDA) is still expected to be DKK 225-250 million.

  • Free cash flow is still expected at approximately minus DKK 700 million.

Hørsholm, 10 November 2017

ALK-Abelló A/S

 

For further information, contact:

Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525

Media: Jeppe Ilkjær, tel. +45 7877 4532, mobile +45 3050 2014 

Today, ALK is hosting a conference call for analysts and investors at 10.00 a.m. (CET) at which Management will review the financial results and the outlook. The conference call will be audio cast on http://ir.alk.net/. Participants for the audio cast are kindly requested to call in before 9.55 a.m. (CET). Danish participants should call in on tel. +45 7022 3500 and international participants should call in on tel. +44 (0) 20 7572 1187 or +1 646 722 4972. Please use the Participant Pin Code: 28359539#. The conference call will also be webcast live on our website, where the related presentation will be made available shortly before the call begins.  

Vedhæftet fil: FM_30_17UK_10112017.pdf

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
Ingen indlæg

Hartmann Q1: Sætter gang i effektiviseringsprogram for at nå 2018-mål

24-05-2018 14:29:06
Fremgang i emballagesalget og et højere teknologisalg prægede årets første kvartal hos emballageproducenten Brødrene Hartmann, der kom ud af perioden med en stigning i både omsætningen og indtjeningen.I første kvartal omsatte virksomheden for 624 mio. kr. mod 572 mio. kr. i samme periode af 2017, og fremgangen kom, på trods af at valutakurser påvirkede omsætningen i år med 55 mio. kr. Det fremgår ..

Pandora/Carnegie: Ser nedjustering komme senere på året

24-05-2018 09:59:22
Smykkekoncernen Pandora har kurs mod en nedjustering senere på året, vurderer Carnegie, som skærer gevaldigt i kursmålet for aktie til 400 kr. fra før 700 kr. og sænker anbefalingen til "sælg" fra "hold". Finanshusets Pandora-analytiker, Lars Topholm, peger også på, at det kan blive nødvendigt at få nye kræfter ind til at få gennemført de nødvendige ændringer i selskabet og genskabe tilliden. Regn..

TCM: Kapitalfond har solgt alle aktier seks måneder efter børsnotering

24-05-2018 08:35:40
Majoritetsaktionæren Innovator International, der ejes af kapitalfonden IK Investment Partners, har solgt alle sine aktier i den danske køkkenkoncern TCM Group.Salget af de i alt 1,97 mio. aktier er solgt gennem en accelereret bookbuiding-proces til institutionelle investorer for 98 kr. per aktie, skriver Bloomberg News.Torsdag er det præcist seks måneder siden, at TCM Group havde første handelsda..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Pandora/Carnegie: Ser nedjustering komme senere på året
2
Bavarian Q1: Lav omsætning giver trecifret millionunderskud
3
Pandora/Carnegie: Sænker anbefalingen til "sælg" fra "hold" - NY
4
Norwegian suser til vejrs efter historie om Ryanair-interesse
5
Torsdagens aktier: Pandora og Ørsted trak C25 i rødt

Relaterede aktiekurser

ALK-Abelló B A/S 1.012,00 -1,2% Fald i aktiekurs

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2018  Disclaimer  |  Cookie- og privatlivspolitik  |  Persondatapolitik
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
25. maj 2018 07:22:55
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20180524.2 - EUROWEB5 - 2018-05-25 07:22:55 - 2018-05-25 07:22:55 - 1 - Website: OKAY